Palo Alto Investors’s Alder Biopharmaceuticals ALDR Stock Holding History

Palo Alto Investors’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,861,630	Closed	-$35.1M	–	38
2019 Q3	$35.1M	Hold	1,861,630	–	–	2.34%	17
2019 Q2	$21.9M	Hold	1,861,630	–	–	1.07%	21
2019 Q1	$25.4M	Hold	1,861,630	–	–	1.06%	22
2018 Q4	$19.1M	Buy	1,861,630 +8,529	+0.5%	+$109K	1.02%	23
2018 Q3	$30.9M	Hold	1,853,101	–	–	1.25%	22
2018 Q2	$29.3M	Buy	1,853,101 +3,269	+0.2%	+$49.7K	1.17%	21
2018 Q1	$23.5M	Buy	1,849,832 +9,586	+0.5%	+$139K	1%	23
2017 Q4	$21.1M	Buy	1,840,246 +1,775,846	+2,758%	+$19.8M	0.91%	22
2017 Q3	$789K	Buy	+64,400	New	+$671K	0.03%	36

Palo Alto Investors's ALDR Position: Q4 2019 in Review

Palo Alto Investors sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 1,861,630 shares — an estimated $35.1M sold.

Palo Alto Investors first reported a position in ALDR in Q3 2017 and held it in 9 quarters. The position peaked at $35.1M in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.

Palo Alto Investors reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
Palo Alto Investors sold 1,861,630 Alder Biopharmaceuticals shares in Q4 2019, an estimated $35.1M.
Palo Alto Investors first reported a position in Alder Biopharmaceuticals in Q3 2017 and held it in 9 quarters.
Palo Alto Investors's Alder Biopharmaceuticals position peaked at $35.1M in Q3 2019.
0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.

Based on Palo Alto Investors's 13F filing for Q4 2019, filed 14 Feb 2020.